Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CMP Therapeutics (CMPT), a company that develops products for colds, flu and allergy based on b 1-3 N-acetyl glucosamine (chitin), has appointed Neill Moray Mackenzie as the new CEO of the company
Subscribe to our email newsletter
Dr Mackenzie brings to CMPT a long record of executive board level management within the biotechnology and pharmaceutical industries at companies including Cambridge Genetics Ltd, Oxford Biomedica plc (an LSE listed company), Avidex Ltd (now Immunocore) and
Before being appointed as the CEO, Dr Mackenzie was the SVP for business development and corporate strategy at Medigene and CEO of Roji Ltd (London).
Achim Kaufhold, chairman of CMPT, said: “Now is a pivotal time for CMPT as we move into advanced clinical development for our lead product and we are delighted to welcome Dr Mackenzie as CEO.”
Dr Mackenzie said: “I am delighted to have been chosen for this role. With a lead compound that has Over-The-Counter (OTC) potential as a treatment for the common cold we hope to be ready for the market shortly after we have completed clinical trials over the next two years.”